APL during gefitinib treatment for non-small-cell lung cancer [8]

New England Journal of Medicine

Volumn 352, Issue 8, 2005, Pages 843-

  Uchida, Akiko ^a   Matsuo, Keitaro ^b   Tanimoto, Mitsune ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR; GEFITINIB; GYRASE INHIBITOR; ANTINEOPLASTIC AGENT; QUINAZOLINE DERIVATIVE;

ACUTE GRANULOCYTIC LEUKEMIA; ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER INCIDENCE; CANCER RADIOTHERAPY; DRUG EFFICACY; HUMAN; LETTER; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; RISK FACTOR; ADENOCARCINOMA; AGED; CASE REPORT; CHEMICALLY INDUCED DISORDER; LUNG TUMOR; MIDDLE AGED; SECOND CANCER; SQUAMOUS CELL CARCINOMA;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; LUNG NEOPLASMS; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; QUINAZOLINES;

EID: 19744383708     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200502243520825     Document Type: Letter

References (3)

1. Lawrence DS, Niu J. Protein kinase inhibitors: the tyrosine-specific protein kinases. Pharmacol Ther 1998;77:81-114.
2. Beaumont M, Sanz M, Carli PM, et al. Therapy-related acute promyelocytic leukemia. J Clin Oncol 2003;21:2123-37.
3. Mauritzson N, Albin M, Rylander L, et al. Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976-1993 and on 5098 unselected cases reported in the literature 1974-2001. Leukemia 2002;16:2366-78.